CARTs on the road for myeloma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24919574.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0721 and PMC identifier 4119563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptors redirect T cells to surface antigens. Discovery and validation of appropriate target antigens expands the possible indications for chimeric-antigen receptor (CAR) T cells. CS1 is expressed at high levels by multiple myeloma cells, but also to some extent on other lymphocytes. CS1 may be a viable target for CAR T cells in multiple myeloma.
Medical subject headings
- Cytotoxicity, Immunologic
- Genetic Engineering
- Multiple Myeloma
- Receptors, Antigen, T-Cell
- Receptors, Immunologic
- T-Lymphocytes